Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

Merck posted strong Q4 earnings, with a 7% revenue increase to $15.62 billion, beating expectations. Growth was driven by ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with the ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...